⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CGEM News
Cullinan Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
CGEM
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
globenewswire.com
CGEM
Form 8-K
sec.gov
CGEM
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
globenewswire.com
CGEM
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
globenewswire.com
CGEM
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
globenewswire.com
CGEM
Form 8-K
sec.gov
CGEM
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
globenewswire.com
CGEM
Form 8-K
sec.gov
CGEM
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
globenewswire.com
CGEM